Nuria Romero-Laorden
YOU?
Author Swipe
View article: Redefining Prostate Cancer Precision: Radiogenomics, Theragnostics, and AI-Driven Biomarkers
Redefining Prostate Cancer Precision: Radiogenomics, Theragnostics, and AI-Driven Biomarkers Open
Background/Objectives: Prostate cancer is the most prevalent malignancy in men and remains a leading cause of cancer-related mortality worldwide. Conventional imaging modalities exhibit limited sensitivity, particularly in the context of d…
View article: Redefining Prostate Cancer Precision: Radiogenomics, Theragnostics, and AI- Driven Biomarkers
Redefining Prostate Cancer Precision: Radiogenomics, Theragnostics, and AI- Driven Biomarkers Open
Background/Objectives: Prostate cancer is the most prevalent malignancy in men and remains a leading cause of cancer-related mortality worldwide. Conventional imaging modalities exhibit limited sensitivity, particularly in the context of d…
View article: Beyond Visualization: Advanced Imaging, Theragnostics and Biomarker Integration in Urothelial Bladder Cancer
Beyond Visualization: Advanced Imaging, Theragnostics and Biomarker Integration in Urothelial Bladder Cancer Open
Background/Objectives: Bladder cancer is characterized by high recurrence and progression rates, posing a challenge to current diagnostic and treatment strategies. This review aims to provide a comprehensive overview of emerging technologi…
View article: BRCA1/2 and homologous recombination repair alterations in high- and low-volume metastatic hormone-sensitive prostate cancer: prevalence and impact on outcomes
BRCA1/2 and homologous recombination repair alterations in high- and low-volume metastatic hormone-sensitive prostate cancer: prevalence and impact on outcomes Open
View article: Immunome profiling in prostate cancer: a guide for clinicians
Immunome profiling in prostate cancer: a guide for clinicians Open
Tumor immune microenvironment (TIME) plays a key role to understand how tumors respond to prostate cancer (PC) therapies and potential mechanisms of resistance. Previous research has suggested that specific genomic aberrations, such as mic…
View article: LB001 Patient characteristics and disease progression throughout prostate cancer stages: Results from SRealProstate in Spain
LB001 Patient characteristics and disease progression throughout prostate cancer stages: Results from SRealProstate in Spain Open
View article: P227 Differences in immunological cell populations between peripheral blood and tumor tissue in patients with NMIBC of varied differentiation grades
P227 Differences in immunological cell populations between peripheral blood and tumor tissue in patients with NMIBC of varied differentiation grades Open
View article: P153 Treatment patterns and outcomes in elderly patients with Castration-Resistant Prostate Cancer (mCRPC): A real-world data analysis
P153 Treatment patterns and outcomes in elderly patients with Castration-Resistant Prostate Cancer (mCRPC): A real-world data analysis Open
View article: Wandering Liver: A Case Report With Clinical and Radiological Insights
Wandering Liver: A Case Report With Clinical and Radiological Insights Open
View article: MAML3-fusions modulate vascular and immune tumour microenvironment and confer high metastatic risk in pheochromocytoma and paraganglioma
MAML3-fusions modulate vascular and immune tumour microenvironment and confer high metastatic risk in pheochromocytoma and paraganglioma Open
View article: 62P A multi-center real-world study of the efficacy and safety of PARP inhibitors in patients with ovarian cancer in Spain
62P A multi-center real-world study of the efficacy and safety of PARP inhibitors in patients with ovarian cancer in Spain Open
PARP inhibitors (PARPi) have changed the treatment paradigm in ovarian cancer. The objective of this collaborative study among 21 Spanish hospitals is to collect real-world data on the efficacy and safety of ovarian cancer patients treated…
View article: Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes
Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes Open
Worse outcomes were observed for mCRPC patients in the BRCA subgroup compared with non-BRCA subgroups, either HRR non-BRCA or non-HRR. Despite its heterogeneity, the HRR non-BRCA subgroup presented worse outcomes than the non-HRR subgroup.…
View article: Supplementary Material for: Is older age an independent prognostic factor of survival in metastatic colorectal cancer?
Supplementary Material for: Is older age an independent prognostic factor of survival in metastatic colorectal cancer? Open
Introduction: Older patients (>75 years) with advanced colorectal cancer (CRC) may have worse survival than non-older patients. We hypothesized that, rather than age alone, concurrent factors may be more relevant for real-world survival. M…
View article: MAML3-fusions modulate Vascular and Immune Tumor Microenvironment and Confer High Metastatic Risk in Pheochromocytoma and Paraganglioma
MAML3-fusions modulate Vascular and Immune Tumor Microenvironment and Confer High Metastatic Risk in Pheochromocytoma and Paraganglioma Open
Background Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumors that encompass a genetically heterogeneous disease. Approximately 20-25% of diagnosed cases develop metastases, for which there is an absence of predict…
View article: Mutational profile of hormone-sensitive and castration-resistant metastatic prostate cancer
Mutational profile of hormone-sensitive and castration-resistant metastatic prostate cancer Open
View article: 1469P The role of the CXCL12/CXCR4 pathway in the immunotherapy of non-small cell lung cancer
1469P The role of the CXCL12/CXCR4 pathway in the immunotherapy of non-small cell lung cancer Open
View article: Tertiary lymphoid structures and B lymphocytes: a promising therapeutic strategy to fight cancer
Tertiary lymphoid structures and B lymphocytes: a promising therapeutic strategy to fight cancer Open
Tertiary lymphoid structures (TLSs) are clusters of lymphoid cells with an organization that resembles that of secondary lymphoid organs. Both structures share common developmental characteristics, although TLSs usually appear in chronical…
View article: Usefulness and real-world outcomes of next generation sequencing testing in patients with cancer: an observational study on the impact of selection based on clinical judgement
Usefulness and real-world outcomes of next generation sequencing testing in patients with cancer: an observational study on the impact of selection based on clinical judgement Open
View article: Data from Targeted Sequencing Reveals Low-Frequency Variants in <i>EPHA</i> Genes as Markers of Paclitaxel-Induced Peripheral Neuropathy
Data from Targeted Sequencing Reveals Low-Frequency Variants in <i>EPHA</i> Genes as Markers of Paclitaxel-Induced Peripheral Neuropathy Open
Purpose: Neuropathy is the dose-limiting toxicity of paclitaxel and a major cause for decreased quality of life. Genetic factors have been shown to contribute to paclitaxel neuropathy susceptibility; however, the major causes for in…
View article: Data from Targeted Sequencing Reveals Low-Frequency Variants in <i>EPHA</i> Genes as Markers of Paclitaxel-Induced Peripheral Neuropathy
Data from Targeted Sequencing Reveals Low-Frequency Variants in <i>EPHA</i> Genes as Markers of Paclitaxel-Induced Peripheral Neuropathy Open
Purpose: Neuropathy is the dose-limiting toxicity of paclitaxel and a major cause for decreased quality of life. Genetic factors have been shown to contribute to paclitaxel neuropathy susceptibility; however, the major causes for in…
View article: Supplementary Material UNMARKED from Targeted Sequencing Reveals Low-Frequency Variants in <i>EPHA</i> Genes as Markers of Paclitaxel-Induced Peripheral Neuropathy
Supplementary Material UNMARKED from Targeted Sequencing Reveals Low-Frequency Variants in <i>EPHA</i> Genes as Markers of Paclitaxel-Induced Peripheral Neuropathy Open
Supplementary Table 1. Non synonymous coding and splicing site variants in the discovery series targeted sequencing. Supplementary Table 2. Association of common non-synonymous coding variants with paclitaxel-induced neuropathy.
View article: Supplementary Material UNMARKED from Targeted Sequencing Reveals Low-Frequency Variants in <i>EPHA</i> Genes as Markers of Paclitaxel-Induced Peripheral Neuropathy
Supplementary Material UNMARKED from Targeted Sequencing Reveals Low-Frequency Variants in <i>EPHA</i> Genes as Markers of Paclitaxel-Induced Peripheral Neuropathy Open
Supplementary Table 1. Non synonymous coding and splicing site variants in the discovery series targeted sequencing. Supplementary Table 2. Association of common non-synonymous coding variants with paclitaxel-induced neuropathy.
View article: A Comprehensive Analysis of Immune Response in Patients with Non-Muscle-Invasive Bladder Cancer
A Comprehensive Analysis of Immune Response in Patients with Non-Muscle-Invasive Bladder Cancer Open
Background. Bladder carcinoma has elevated morbimortality due to its high recurrence and progression in localized disease. A better understanding of the role of the tumor microenvironment in carcinogenesis and response to treatment is need…
View article: The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA Repair
The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA Repair Open
BRCA1 and BRCA2 are the most recognized tumor-suppressor genes involved in double-strand DNA break repair through the homologous recombination (HR) system. Widely known for its role in hereditary cancer, HR deficiency (HRD) has turned out …
View article: Peripheral Blood Mononuclear Cells Predict Therapeutic Efficacy of Immunotherapy in NSCLC
Peripheral Blood Mononuclear Cells Predict Therapeutic Efficacy of Immunotherapy in NSCLC Open
In lung cancer immunotherapy, biomarkers to guide clinical decisions are limited. We now explore whether the detailed immunophenotyping of circulating peripheral blood mononuclear cells (PBMCs) can predict the efficacy of anti-PD-1 immunot…
View article: Immunotherapy in Advanced Prostate Cancer: Current Knowledge and Future Directions
Immunotherapy in Advanced Prostate Cancer: Current Knowledge and Future Directions Open
The advent of immunotherapy has revolutionized cancer treatment. Unfortunately, this has not been the case for metastatic castration-resistant prostate cancer (mCRPC), likely due to the heterogeneous and immune-suppressive microenvironment…
View article: Emotional Distress in Cancer Patients During the First Wave of the COVID-19 Pandemic
Emotional Distress in Cancer Patients During the First Wave of the COVID-19 Pandemic Open
Background: The COVID-19 pandemic has caused mental health problems worldwide. The psychopathological implications of COVID-19 in cancer patients have rarely been addressed. Considering the increased vulnerability of oncology patients, thi…
View article: 1621P Emotional distress in cancer patients during the first wave of the COVID-19 pandemic in Madrid
1621P Emotional distress in cancer patients during the first wave of the COVID-19 pandemic in Madrid Open
View article: Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients
Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Open
Circulating tumor cell (CTC) enumeration and changes following treatment have been demonstrated to be superior to PSA response in determining mCRPC outcome in patients receiving AR signaling inhibitors but not taxanes. We carried out a poo…
View article: 640P Quality of life and survival in elderly metastatic castration-resistant prostate cancer (mCRPC) patients (Pts) treated with docetaxel
640P Quality of life and survival in elderly metastatic castration-resistant prostate cancer (mCRPC) patients (Pts) treated with docetaxel Open